Rapid Tests Market by Product, Application, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4580490
  • Report
  • 235 pages
  • Allied Analytics LLP
1 of 4

The global rapid tests market generated $21,455 million in 2016, and is projected to reach $39,103 million by 2023, growing at a CAGR of 8.9% from 2017 to 2023. Rapid tests are diagnostic assays designed for use where preliminary screening tests need to be conducted. These tests are easy, quick, and provide specific results; hence, are used in settings with limited resources. Rapid tests are incorporated in diagnosis of different diseases and health conditions such as HIV, influenza, malaria, cancer, pregnancy & fertility, and others.

The rapid tests market is expected to grow at a significant rate during the forecast period, owing to increase in awareness regarding early diagnosis of disease, prevalence of infectious diseases, and need for low cost as well as accurate diagnostic testing. In addition, growth in personalized care and increased promotional activities by manufacturers encourage the usage rapid tests, which further facilitate the growth of the market. However, stringent government regulations for the approval of rapid tests and recall of several products due to false results are expected to impede the market growth.

The global rapid tests market is segmented based on product, application, end user, and region. Based on product, the market is bifurcated into over-the-counter (OTC) rapid test product and professional rapid test product. By application, the market is classified into infectious disease, cardiology, oncology, pregnancy & fertility, toxicology, glucose monitoring, and others. According to end user, it is segmented as hospital & clinic, diagnostic laboratory, home care, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product

Over-the-counter (OTC) Rapid Test Product
Professional Rapid Test Product

By Application

Infectious Disease
HPV
Hepatitis
Influenza
Malaria
HIV
Others
Cardiology
Oncology
Pregnancy & Fertility
Toxicology
Glucose Monitoring
Others

By End User

Hospital & Clinic
Diagnostic Laboratory
Home Care
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Akers Biosciences, Inc.
Alere Inc. (Abbott Laboratories)
Becton, Dickinson and Company
Bio-rad Laboratories, Inc.
Cepheid, Inc.
Hologic, Inc.
Meridian Bioscience, Inc.
OraSure Technologies, Inc.
Quidel Corporation
Roche Diagnostics

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Abingdon Health
ARKRAY, Inc.
Biocom Diagnostics
Biomerica, Inc.
Demeditec Diagnostics GmbH
Epitope Diagnostics Inc.
NanoRepro AG.
Randox Laboratories Ltd.

READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Benefits of rapid tests over laboratory testing
3.4.1.2. Increase in initiatives of government and nonprofit organizations towards health awareness
3.4.1.3. Increase in healthcare expenditure worldwide
3.4.2. Restraint
3.4.2.1. Inadequate reimbursement policies for rapid test diagnostics
3.4.3. Opportunities
3.4.3.1. Growth opportunities in the emerging markets
3.4.3.2. Increase in prevalence of various chronic and infectious diseases across the world
3.4.4. Impact analysis

CHAPTER 4: RAPID TESTS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Over-the-counter (OTC) rapid test products
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Professional rapid test products
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

CHAPTER 5: RAPID TESTS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious disease
5.2.1. Market size and forecast, by type
5.2.1.1. HPV rapid tests
5.2.1.1.1. Market size and forecast
5.2.1.2. Hepatitis rapid tests
5.2.1.2.1. Market size and forecast
5.2.1.3. Influenza rapid tests
5.2.1.3.1. Market size and forecast
5.2.1.4. Malaria rapid tests
5.2.1.4.1. Market size and forecast
5.2.1.5. HIV rapid tests
5.2.1.5.1. Market size and forecast
5.2.1.6. Other infectious disease rapid tests
5.2.1.6.1. Market size and forecast
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Cardiology
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Oncology
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Pregnancy & fertility
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Toxicology
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
5.7. Glucose monitoring
5.7.1. Market size and forecast
5.7.2. Market analysis, by country
5.8. Other applications
5.8.1. Market size and forecast
5.8.2. Market analysis, by country

CHAPTER 6: RAPID TESTS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals & clinics
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Diagnostic laboratories
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Home care
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
6.5. Others
6.5.1. Market size and forecast
6.5.2. Market analysis, by country

CHAPTER 7: RAPID TESTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. rapid tests market, by product
7.2.2.1.2. U.S. rapid tests market, by application
7.2.2.1.3. U.S. rapid tests market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada rapid tests market, by product
7.2.2.2.2. Canada rapid tests market, by application
7.2.2.2.3. Canada rapid tests market, by end user
7.2.2.3. Mexico
7.2.2.3.1. Mexico rapid tests market, by product
7.2.2.3.2. Mexico rapid tests market, by application
7.2.2.3.3. Mexico rapid tests market, by end user
7.2.3. North America rapid tests market, by product
7.2.4. North America rapid tests market, application
7.2.5. North America rapid tests market, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany rapid tests market, by product
7.3.2.1.2. Germany rapid tests market, by application
7.3.2.1.3. Germany rapid tests market, by end user
7.3.2.2. France
7.3.2.2.1. France rapid tests market, by product
7.3.2.2.2. France rapid tests market, by application
7.3.2.2.3. France rapid tests market, by end user
7.3.2.3. UK
7.3.2.3.1. UK rapid tests market, by product
7.3.2.3.2. UK rapid tests market, by application
7.3.2.3.3. UK rapid tests market, by end user
7.3.2.4. Italy
7.3.2.4.1. Italy rapid tests market, by product
7.3.2.4.2. Italy rapid tests market, by application
7.3.2.4.3. Italy rapid tests market, by end user
7.3.2.5. Spain
7.3.2.5.1. Spain rapid tests market, by product
7.3.2.5.2. Spain rapid tests market, by application
7.3.2.5.3. Spain rapid tests market, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe rapid tests market, by product
7.3.2.6.2. Rest of Europe rapid tests market, by application
7.3.2.6.3. Rest of Europe rapid tests market, by end user
7.3.3. Europe rapid tests market, by product
7.3.4. Europe rapid tests market, application
7.3.5. Europe rapid tests market, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan rapid tests market, by product
7.4.2.1.2. Japan rapid tests market, by application
7.4.2.1.3. Japan rapid tests market, by end user
7.4.2.2. China
7.4.2.2.1. China rapid tests market, by product
7.4.2.2.2. China rapid tests market, by application
7.4.2.2.3. China rapid tests market, by end user
7.4.2.3. Australia
7.4.2.3.1. Australia rapid tests market, by product
7.4.2.3.2. Australia rapid tests market, by application
7.4.2.3.3. Australia rapid tests market, by end user
7.4.2.4. India
7.4.2.4.1. India rapid tests market, by product
7.4.2.4.2. India rapid tests market, by application
7.4.2.4.3. India rapid tests market, by end user
7.4.2.5. South Korea
7.4.2.5.1. South Korea rapid tests market, by product
7.4.2.5.2. South Korea rapid tests market, by application
7.4.2.5.3. South Korea rapid tests market, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific rapid tests market, by product
7.4.2.6.2. Rest of Asia-Pacific rapid tests market, by application
7.4.2.6.3. Rest of Asia-Pacific rapid tests market, by end user
7.4.3. Asia-Pacific rapid tests market, by product
7.4.4. Asia-Pacific rapid tests market, application
7.4.5. Asia-Pacific rapid tests market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil rapid tests market, by product
7.5.2.1.2. Brazil rapid tests market, by application
7.5.2.1.3. Brazil rapid tests market, by end user
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia rapid tests market, by product
7.5.2.2.2. Saudi Arabia rapid tests market, by application
7.5.2.2.3. Saudi Arabia rapid tests market, by end user
7.5.2.3. South Africa
7.5.2.3.1. South Africa rapid tests market, by product
7.5.2.3.2. South Africa rapid tests market, by application
7.5.2.3.3. South Africa rapid tests market, by end user
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA rapid tests market, by product
7.5.2.4.2. Rest of LAMEA rapid tests market, by application
7.5.2.4.3. Rest of LAMEA rapid tests market, by end user
7.5.3. LAMEA rapid tests market, by product
7.5.4. LAMEA rapid tests market, application
7.5.5. LAMEA rapid tests market, by end user

CHAPTER 8: COMPANY PROFILES
8.1. Akers Biosciences, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Abbott Laboratories (Alere Inc.)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Becton, Dickinson and Company
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Bio-Rad Laboratories, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Danaher Corporation (Cepheid, Inc.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Hologic, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Meridian Bioscience, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. OraSure Technologies, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Quidel Corporation
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. F. Hoffmann-La Roche AG (Roche Diagnostics)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Rapid Tests Market, by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023" the market was valued at $21,455 million in 2016, and is expected to reach $39,103 million by 2023, growing at a CAGR of 8.9% from 2017 to 2023.

Rapid tests provide diagnostic results spontaneously to patients and are preferably used in preliminary screenings as well as and in settings with limited resources. Increase in incidence of chronic diseases such as diabetes, cardiovascular disorders, & cancer, rise in awareness about rapid tests owing to the test convenience, and low cost of the tests, majorly drive the growth of the rapid tests market. In addition, other factors, such as speed of diagnosis, specificity, and stability, fuel the market growth globally.

Based on product, the professional rapid test products occupied the largest share in 2016, and is anticipated to continue its dominance during the forecast period, owing to increased demand for rapid tests in hospitals and mandated government policies for screening of diseases such as HIV, malaria, influenza, and others. However, the over-the-counter (OTC) rapid test product segment is expected to grow at the highest CAGR from 2017 to 2023.

Based on application, the glucose monitoring segment occupied the largest share in 2016, and is anticipated to dominate the market during the forecast period, due to increase in prevalence of diabetes and growth in awareness of home care glucose rapid tests kits. On the other side, infectious disease segment is expected to exhibit the fastest market growth during the forecast period due to surge in prevalence of infectious disease and rise in demand for low cost & accurate rapid tests for preliminary infectious disease testing.

Based on end user, the home care segment occupied the largest share in 2016, and is anticipated to continue its dominance during the forecast period, due to increased demand for personalized care rapid tests and cost-efficient product availability. On the other side, the hospital & clinic segment is anticipated to exhibit the fastest market growth during the forecast period due to increase in demand for rapid tests.

Key findings of the Rapid Tests Market:

Based on product, the over-the-counter (OTC) rapid test product segment is expected to show the fastest growth, from 2017 to 2023.
Based on application, the glucose monitoring segment held approximately half of the global market share in 2016 and is expected to remain dominant throughout the forecast period.
Based on application, the infectious disease segment exhibited double digit growth rate.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 10.5% during the forecast period.

North America accounted for more than two-fifths share of the global rapid tests market in 2016 and is expected to remain dominant throughout the forecast period. This was attributed to the extensive use of personalized care medical devices, well-developed healthcare infrastructure, and rise in health care awareness. On the other hand, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to awareness about health and rapid tests.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll